Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma

Tumor Biology

Volumn 36, Issue 3, 2014, Pages 1561-1566

  Wang, Yun ^a   Li, Hongxia ^a   Liang, Qi ^a   Liu, Bin ^b   Mei, Xiaqi ^a   Ma, Yingji ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Heilongjiang Ctr for Dis Control   (China)

Author keywords

Oncogene; PD 1; Phosphorylation; Sorafenib; Therapeutic antibody

Indexed keywords

CARBANILAMIDE DERIVATIVE; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NICOTINAMIDE; PROGRAMMED DEATH 1 LIGAND 1; SORAFENIB;

ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LIVER NEOPLASMS; METABOLISM; MOUSE; NATURAL KILLER CELL; NUDE MOUSE; PROCEDURES; RETROSPECTIVE STUDY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MICE; MICE, NUDE; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 84930922604     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2722-2     Document Type: Article

References (40)

1. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol. 2012;39(4):486–92.
2. Vinas A et al. Mapping of DNA sex-specific markers and genes related to sex differentiation in turbot (Scophthalmus maximus). Mar Biotechnol (NY). 2012;14(5):655–63.
3. Ng CK et al. Deciphering the Sox-Oct partner code by quantitative cooperativity measurements. Nucleic Acids Res. 2012;40(11):4933–41.
4. Coco C et al. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. J Exp Clin Cancer Res. 2012;31:71.
5. Zhang W et al. Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res. 2008;68(8):2764–72.
6. Scott EL, Brann DW. Estrogen regulation of Dkk1 and Wnt/beta-catenin signaling in neurodegenerative disease. Brain Res. 2013;1514:63–74.
7. Mok TS et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.
8. Mitsudomi T et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–8.
9. Zhou C et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced PD-L1 mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.
10. Failli V, Bachy I, Rétaux S. Expression of the LIM-homeodomain gene Lmx1a (dreher) during development of the mouse nervous system. Mech Dev. 2002;118(1):225–8.
11. Murray KD, Choudary PV, Jones EG. Nucleus- and cell-specific gene expression in monkey thalamus. Proc Natl Acad Sci. 2007;104(6):1989–94.
12. Fu W et al. Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies. MAbs. 2014;6(4):978–90.
13. Hu S et al. Comparison of the inhibition mechanisms of adalimumab and infliximab in treating tumor necrosis factor α-associated diseases from a molecular view. J Biol Chem. 2013;288(38):27059–67.
14. Ferlay J et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
15. Fujimoto-Ouchi K et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59(6):795–805.
16. Bang Y-J et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
17. Kute T et al. Development of Herceptin resistance in breast cancer cells. Cytometry A. 2004;57(2):86–93.
18. Lu Y et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 2001;93(24):1852–7.
19. Nagy P et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005;65(2):473–82.
20. Price‐Schiavi SA et al. Rat Muc4 (sialomucin complex) reduces binding of anti‐ErbB2 antibodies to tumor cell surfaces, a potential mechanism for Herceptin resistance. Int J Cancer. 2002;99(6):783–91.
21. Scaltriti M et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628–38.
22. Park J-G et al. Characteristics of cell lines established from human gastric carcinoma. Cancer Res. 1990;50(9):2773–80.
23. Kim SY et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 2008;32(1):89–95.
24. Cho H-S et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421(6924):756–60.
25. Knuefermann C et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003;22(21):3205–12.
26. Scagliotti GV et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.
27. Li YM et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004;6(5):459–69.
28. Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–43.
29. Konecny GE et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630–9.
30. Schnitt SJ. Breast cancer in the 21st century: neu opportunities and neu challenges. Mod Pathol. 2001;14(3):213–8.
31. Bass AJ et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–42.
32. Hussenet T et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One. 2010;5(1):e8960.
33. Yuan P et al. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One. 2010;5(2):e9112.
34. Tompkins DH et al. Sox2 activates cell proliferation and differentiation in the respiratory epithelium. Am J Respir Cell Mol Biol. 2011;45(1):101–10.
35. Tompkins DH et al. Sox2 is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PLoS One. 2009;4(12):e8248.
36. Aksoy I et al. Sox transcription factors require selective interactions with Oct4 and specific transactivation functions to mediate reprogramming. Stem Cells. 2013;31(12):2632–46.
37. Therasse P et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–16.
38. Franklin MC et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317–28.
39. Agus DB et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2(2):127–37.
40. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol. 1999;19(10):6845–57.